3-(4-溴苯基)异噁唑-5-胺 | 119162-53-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-(4-溴苯基)异噁唑-5-胺
• 中文别名: 3-(4-溴苯基)-5-氨基异噁唑；3-(4-溴代苯基)-5-异恶唑啉
• 英文名称: 3-(4-bromophenyl)isoxazol-5-amine
• 英文别名: 5-amino-3-(4-bromophenyl)isoxazole；3-(4-bromophenyl)-1,2-oxazol-5-amine
• CAS: 119162-53-7
• 化学式: C₉H₇BrN₂O
• mdl: MFCD06199354
• 分子量: 239.071
• InChiKey: RKWRDXQHQYRFCX-UHFFFAOYSA-N

物化性质

• 熔点：
  160-163°

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  52
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2934999090

SDS

---

Section 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE
Product identifiers
Product name : 3-(4-Bromophenyl)-5-isoxazolamine
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

Section 2. HAZARDS IDENTIFICATION
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008 [EU-GHS/CLP]
Acute toxicity, Oral (Category 3)
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Harmful if swallowed.
Label elements
Labelling according Regulation (EC) No 1272/2008 [CLP]
Pictogram
Signal word Danger
Hazard statement(s)
H301 Toxic if swallowed.
Precautionary statement(s)
P301 + P310 IF SWALLOWED: Immediately call a POISON CENTER or doctor/
physician.
Supplemental Hazard none
Statements
According to European Directive 67/548/EEC as amended.
Hazard symbol(s)
R-phrase(s)
R22 Harmful if swallowed.
S-phrase(s) none
Other hazards - none

---

Section 3. COMPOSITION/INFORMATION ON INGREDIENTS
Substances
Formula : C9H7BrN2O
Molecular Weight : 239,07 g/mol
Component Concentration
3-(4-Bromophenyl)-5-isoxazolamine
-

---

Section 4. FIRST AID MEASURES
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Take victim immediately to hospital. Consult a physician.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.
Indication of any immediate medical attention and special treatment needed
no data available

---

Section 5. FIREFIGHTING MEASURES
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides, nitrogen oxides (NOx), Hydrogen bromide gas
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

Section 6. ACCIDENTAL RELEASE MEASURES
Personal precautions, protective equipment and emergency procedures
Wear respiratory protection. Avoid dust formation. Avoid breathing vapors, mist or gas. Ensure adequate
ventilation. Evacuate personnel to safe areas. Avoid breathing dust.
Environmental precautions
Prevent further leakage or spillage if safe to do so. Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

Section 7. HANDLING AND STORAGE
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.Normal measures for preventive fire
protection.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Specific end uses
no data available

---

Section 8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Avoid contact with skin, eyes and clothing. Wash hands before breaks and immediately after handling
the product.
Personal protective equipment
Eye/face protection
Face shield and safety glasses Use equipment for eye protection tested and approved under
appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Where risk assessment shows air-purifying respirators are appropriate use a full-face particle
respirator type N99 (US) or type P2 (EN 143) respirator cartridges as a backup to engineering
controls. If the respirator is the sole means of protection, use a full-face supplied air respirator. Use
respirators and components tested and approved under appropriate government standards such
as NIOSH (US) or CEN (EU).

---

Section 9. PHYSICAL AND CHEMICAL PROPERTIES
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing Melting point/range: 164 - 166 °C
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evaporation rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- log Pow: 2,804
octanol/water
p) Autoignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

Section 10. STABILITY AND REACTIVITY
Reactivity
no data available
Chemical stability
no data available
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available

---

Section 11. TOXICOLOGICAL INFORMATION
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitization
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
no data available
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Potential health effects
Inhalation
May be harmful if inhaled. May cause respiratory tract irritation.
Ingestion Toxic if swallowed.
Skin May be harmful if absorbed through skin. May cause skin irritation.
Eyes May cause eye irritation.
Signs and Symptoms of Exposure
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.
Additional Information
RTECS: Not available

---

Section 12. ECOLOGICAL INFORMATION
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
no data available
Other adverse effects
no data available

---

Section 13. DISPOSAL CONSIDERATIONS
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed
professional waste disposal service to dispose of this material. Dissolve or mix the material with a
combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

Section 14. TRANSPORT INFORMATION
UN number
ADR/RID: 2811 IMDG: 2811 IATA: 2811
UN proper shipping name
ADR/RID: TOXIC SOLID, ORGANIC, N.O.S. (3-(4-Bromophenyl)-5-isoxazolamine)
IMDG: TOXIC SOLID, ORGANIC, N.O.S. (3-(4-Bromophenyl)-5-isoxazolamine)
IATA: Toxic solid, organic, n.o.s. (3-(4-Bromophenyl)-5-isoxazolamine)
Transport hazard class(es)
ADR/RID: 6.1 IMDG: 6.1 IATA: 6.1
Packaging group
ADR/RID: III IMDG: III IATA: III
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

---

Section 15. REGULATORY INFORMATION
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
no data available
Chemical Safety Assessment
no data available

---

Section 16. OTHER INFORMATION
Further information
Copyright 2012 Co. LLC. License granted to make unlimited paper copies for internal use
only.
The above information is believed to be correct but does not purport to be all inclusive and shall be
used only as a guide. The information in this document is based on the present state of our knowledge
and is applicable to the product with regard to appropriate safety precautions. It does not represent any
guarantee of the properties of the product. Corporation and its Affiliates shall not be held
liable for any damage resulting from handling or from contact with the above product. See
and/or the reverse side of invoice or packing slip for additional terms and conditions of sale.

反应信息

• 作为反应物：
  描述：

  3-(4-溴苯基)异噁唑-5-胺 在 iron(II) chloride tetrahydrate 作用下， 以 aq. phosphate buffer 、 乙醇 、 乙腈 为溶剂， 20.0~37.0 ℃ 、101.33 kPa 条件下， 反应 20.0h， 生成 2-amino-3-(4-bromophenyl)-3,3-bis(phenylthio)propanamide
  参考文献：
  名称：

  2H-Azirines作为生物共轭技术中半胱氨酸残基的潜在双功能化学连接物。

  摘要：

  2H-Azirine-2-caboxamides被设计为在非常温和的反应条件下充当新型的双功能硫醇连接基。2H-叠氮基的CN双键的裂解通过硫醇加成和开环过程原位提供氨基酰胺官能团。在室温下不存在任何催化剂的情况下，它可与各种硫醇和2H-叠氮基一起使用。还证明了含半胱氨酸的肽可以在完全水溶液中有效地起作用。

  DOI：

  10.1021/acs.orglett.0c00415
• 作为产物：
  描述：

  4-溴苯甲酰乙腈 在 盐酸羟胺 、 sodium acetate 作用下， 以 甲醇 为溶剂， 以62%的产率得到3-(4-溴苯基)异噁唑-5-胺
  参考文献：
  名称：

  Hoveyda–Grubbs II催化剂：用于一锅可见光促进的环收缩和烯烃复分解反应的有用催化剂

  摘要：

  描述了通过可见光介导的环收缩和异恶唑的烯烃复分解反应合成官能化2 H-叠氮基的一锅反应。发现Hoveyda–Grubbs II催化剂可作为这些转化的光催化剂，使这些过程可以一锅法进行。这项研究为将Grubbs催化剂用作有效的光催化剂提供了一个新的切入点，并且为一锅法进行其他光反应和烯烃复分解提供了可能性。

  DOI：

  10.1021/acs.orglett.8b00971

文献信息

• [EN] NITROGEN-CONTAINING HETEROARYL DERIVATIVES<br/>[FR] DÉRIVÉS HÉTÉROARYLIQUES CONTENANT DE L'AZOTE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2011089132A1

  公开（公告）日：2011-07-28

  The invention is concerned with novel nitrogen-containing heteroaryl derivatives of formula (I) wherein R1, R2, R3, R4, R5, A1, A2, and Y are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds inhibit PDE10A and can be used as medicaments.

  本发明涉及式(I)的新氮杂芳基衍生物，其中R1、R2、R3、R4、R5、A1、A2和Y的定义如描述和权利要求中所述，以及这些化合物的生理可接受的盐和酯。这些化合物可以抑制PDE10A，并可作为药物使用。
• NITROGEN-CONTAINING HETEROARYL DERIVATIVES
  申请人：Bleicher Konrad

  公开号：US20110183979A1

  公开（公告）日：2011-07-28

  The invention is concerned with novel nitrogen-containing heteroaryl derivatives of formula (I) wherein R 1 , R 2 , R 3 , R 4 , R 5 , A 1 , A 2 , and Y are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds inhibit PDE10A and can be used as medicaments.

  本发明涉及式(I)的新氮杂芳基衍生物，其中R1、R2、R3、R4、R5、A1、A2和Y的定义如描述和权利要求中所述，以及这些化合物的生理可接受的盐和酯。这些化合物可以抑制PDE10A，并可作为药物使用。
• [EN] INHIBITING TRABID<br/>[FR] INHIBITION DE TRABID
  申请人：INTEGRAL EARLY DISCOVERY INC

  公开号：WO2020227168A1

  公开（公告）日：2020-11-12

  The present disclosure is directed to compounds of formulas (I) - (VII), which are useful as modulators of TRABID. The compounds are further useful in the inhibition of TRABID and the treatment of diseases or disorders associated with the inhibition of TRABID. For instance, the disclosure is concerned with compounds and compositions for inhibition of TRABID, methods of treating diseases associated with the inhibition of TRABID (e.g., autoimmune inflammatory diseases including, but not limited to, psoriasis), and methods of synthesis of these compounds.

  本公开涉及化合物的结构式(I) - (VII)，这些化合物可作为TRABID的调节剂。这些化合物进一步可用于抑制TRABID并治疗与TRABID抑制相关的疾病或紊乱。例如，本公开涉及用于抑制TRABID的化合物和组合物，治疗与TRABID抑制相关的疾病的方法（例如，包括但不限于自身免疫性炎症性疾病，如牛皮癣），以及这些化合物的合成方法。
• Identification of a nanomolar affinity α-synuclein fibril imaging probe by ultra-high throughput <i>in silico</i> screening
  作者：John J. Ferrie、Zsofia Lengyel-Zhand、Bieneke Janssen、Marshall G. Lougee、Sam Giannakoulias、Chia-Ju Hsieh、Vinayak Vishnu Pagar、Chi-Chang Weng、Hong Xu、Thomas J. A. Graham、Virginia M.-Y. Lee、Robert H. Mach、E. James Petersson

  DOI：10.1039/d0sc02159h

  日期：——

  Ultra-high throughput in silico screening identified molecules that bind to α-synuclein fibrils, which were analyzed by photo-crosslinking, structure-activity studies, and radioligand binding to validate this approach for finding imaging probes.

  超高通量的“体外”筛选确定了能够结合α-突触核蛋白纤维的分子，通过光交联、结构活性研究和放射配体结合进行分析，验证了这种方法用于寻找成像探针。
• Hoveyda–Grubbs II Catalyst: A Useful Catalyst for One-Pot Visible-Light-Promoted Ring Contraction and Olefin Metathesis Reactions
  作者：Yun Ge、Wangbin Sun、Bingbing Pei、Jia Ding、Yaojia Jiang、Teck-Peng Loh

  DOI：10.1021/acs.orglett.8b00971

  日期：2018.5.4

  A one-pot reaction to synthesize functionalized 2H-azirines through visible-light-mediated ring contraction and olefin metathesis of isoxazoles is described. Hoveyda–Grubbs II catalyst was found to function as a photocatalyst for these transformations, allowing these processes to be carried out in a one-pot manner. This study offers a new entry for the application of Grubbs catalysts as efficient photocatalysts

  描述了通过可见光介导的环收缩和异恶唑的烯烃复分解反应合成官能化2 H-叠氮基的一锅反应。发现Hoveyda–Grubbs II催化剂可作为这些转化的光催化剂，使这些过程可以一锅法进行。这项研究为将Grubbs催化剂用作有效的光催化剂提供了一个新的切入点，并且为一锅法进行其他光反应和烯烃复分解提供了可能性。